A study to investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in participants with suspected NASH.

Trial Identifier: D9230C00002
Sponsor: AstraZeneca
NCTID:: NCT05864391
Start Date: March 2023
Primary Completion Date: March 2024
Study Completion Date: March 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, AZ Chandler, AZ, US, 85224
US, CA Montclair, CA, US, 91763
US, FL Hialeah, FL, US, 33016
US, FL Port Orange, FL, US, 32127
US, GA Atlanta, GA, US, 30349
US, IN Indianapolis, IN, US, 46202
US, NC Morehead City, NC, US, 28557
US, PR San Juan, PR, US, 00927
US, TX Houston, TX, US, 77079
US, TX San Antonio, TX, US, 78215
US, TX San Antonio, TX, US, 78229